Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children

Journal of Pediatrics

Volumn 135, Issue 5, 1999, Pages 575-579

  Feder H M , Jr ^a   Beran, J ^a   Van Hoecke, C ^a   Abraham, B ^a   De Clercq, N ^a   Buscarino, C ^a   Parenti, D L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; PROTEIN A;

ADOLESCENT; ARTICLE; BORRELIA BURGDORFERI; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN DISEASE;

EID: 0033498171     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-3476(99)70055-7     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. Lyme disease—United States MMWR Morb Mortal Wkly Rep 44 1995 459 463
2. Centers for Disease Control and Prevention Lyme disease surveillance MMWR Morb Mortal Wkly Rep 40 1991 417 421
3. Centers for Disease Control and Prevention Lyme disease surveillance MMWR Morb Mortal Wkly Rep 46 1997 531 535
4. DJ White HG Chang JL Benach The geographic spread and temporal increase of the Lyme disease epidemic JAMA 266 1991 1230 1236
5. Connecticut Department of Public Health and Addiction Services Lyme disease update Conn Epidemiologist 13 1993 9 10
6. H Feder Jr MA Gerber ML Cartter V Sikand PJ. Krause Prospective assessment of Lyme disease in a school-aged population in Connecticut J Infect Dis 171 1995 1371 1374
7. RT Steigbigel JL. Benach Immunization against Lyme disease: an important first step N Engl J Med 339 1998 263 264
8. UE Schaible MD Kramer K Eichmann M Modolell C Museteanu MM. Simon Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice Proc Natl Acad Sci USA 87 1990 3768 3772
9. E Fikrig SW Barthold N Marcantonio K Deponte FS Kantor RA. Flavell Roles of OspA, OspB and flagellin in protective immunity to Lyme borreliosis in laboratory mice Infect Immun 60 1992 657 661
10. E Fikrig SR Telford SW Barthold FS Kantor A Spielman RA. Flavell Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice Proc Natl Acad Sci USA 89 1992 5418 5421
11. MT Philipp Y Lobet RP Bohm Jr Safety and immunogenicity of recombinant outer surface protein A (OspA) vaccine formulations in the Rhesus monkey J Spirochetal Tickborne Dis 3 1996 1 13
12. C Van Hoecke M Comberbach D De Grave Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults Vaccine 14 1996 1620 1626
13. AC Steere VK Sikand F Meurice Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant N Engl J Med 339 1998 209 215
14. LH Sigal JM Zahradnik P Lavin A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease N Engl J Med 339 1998 216 222
15. Recommendations for test performance and interpretation from the Second International Conference on Serologic Diagnosis of Lyme disease MMWR Morb Mortal Wkly Rep 44 1995 590 591
16. WT Golde J Piesman MC Dolan Reactivity with a specific epitope of outer surface protein A predicts protection from infection with Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 65 1997 882 889
17. TM, recombinant, adjuvanted Borrelia burgdorferi outer surface lipoprotein A (L-OspA) vaccine Presented at the 36th Infectious Diseases Society of America Annual Meeting Abstract No. 705 1998 Nov 12-15 Colo Denver 208